14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
HCTI vs GRML: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, GRML (GRML) captures the overall head-to-head institutional edge over Healthcare Triangle, Inc. (HCTI) on higher Unified Composite conviction (56.8/100 HOLD vs. 36.5/100 SELL) after splitting the core matrix 2–6 (led by Options & Positioning), while HCTI wins 5–1 across the 6-pillar growth and valuation breakdown. HCTI trades at $3.42 (N/M Forward P/E, -57.4% operating margin) versus GRML at $3.51 (N/M Forward P/E, N/A operating margin).
Growth vs. Quality Trade-Off: GRML earns the overall head-to-head edge with a stronger Unified Composite Score (56.8/100 HOLD vs. HCTI 36.5/100 SELL) and -5.32β · 95% Vol risk profile, whereas HCTI leads top-line expansion (+158.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: HCTI is currently in a Breakdown options structure phase (RSI 50.6); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HCTI vs GRML. Trailing 12-month operating profitability (HCTI -57.4% vs GRML N/A) and valuation multiples (HCTI N/M vs GRML N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ HCTI vs GRML Key Questions & Quantitative Answers
As of Nov 16, 2026, GRML (GRML) captures the overall head-to-head institutional edge over Healthcare Triangle, Inc. (HCTI) on higher Unified Composite conviction (56.8/100 HOLD vs. 36.5/100 SELL) after splitting the core matrix 2–6 (led by Options & Positioning), while HCTI wins 5–1 across the 6-pillar growth and valuation breakdown. HCTI trades at $3.42 (N/M Forward P/E, -57.4% operating margin) versus GRML at $3.51 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: GRML earns the overall head-to-head edge with a stronger Unified Composite Score (56.8/100 HOLD vs. HCTI 36.5/100 SELL) and -5.32β · 95% Vol risk profile, whereas HCTI leads top-line expansion (+158.4% YoY revenue growth, N/M PEG, and 5 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: HCTI is currently in a Breakdown options structure phase (RSI 50.6); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
HCTI leads the Growth & Scale pillar: HCTI posts +158.4% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (21.5% gross margin, -57.4% operating margin), compared with GRML at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, HCTI generates $26M in USD-normalized revenue versus N/A for GRML. In operating R&D and SG&A reinvestment, HCTI deploys 78.9% of Rev ($20M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRML.
HCTI screens cheaper on headline valuation multiples. HCTI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-51.0% EBITDA margin), whereas GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HCTI (-57.4% ROE) versus GRML (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, HCTI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (10.92β · 6722% Vol realized risk). By comparison, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.32β · 95% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.